CTOs on the Move

ThromboGenics

www.thrombogenics.com

 
ThromboGenics is an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic and oncology medicines. The Company`s lead product, JETREA® (ocriplasmin), has been approved by the US FDA for the treatment of symptomatic VMA and was launched in January 2013. ThromboGenics signed a strategic partnership with Alcon, a division of Novartis, for the commercialization of JETREA® outside the United States. ThromboGenics is headquartered in Leuven, Belgium, and has offices in Iselin, NJ (US) and Dublin, Ireland. The Company is listed on the NYSE Euronext Brussels exchange under the symbol THR.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Medical Components

Dialysis and Vascular Access Products

Evotec

Evotec is a Winchester, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Galectin Therapeutics

Galectin Therapeutics (NASDAQ: GALT) is applying its leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. Drug candidates based on the Company`s unique carbohydrate technology target galectin proteins which are key mediators of biologic and pathologic function.

Drug Transport, Inc.

Drug Transport, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Bid4Health

Bid4Health is a Bethesda, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.